Lilly Crushes Q2: Revenue Soars 48%, Guidance Raised to $87B
LLY sits 91% above its 52-week low of $623.78.
Summary
Lilly delivered a massive Q2 beat with revenue of $22.97B, up 48% YoY, and adjusted EPS of $8.38, well above consensus. Mounjaro and Zepbound remain the dominant growth engines, generating $9.94B and $4.93B respectively, while the newly launched oral GLP-1 Foundayo posted $98M in its first full quarter. Management raised full-year revenue guidance to $85B-$87B, signaling confidence in sustained demand. The quarter also included $2.78B in acquired IPR&D charges from the Aktis Oncology and Centessa acquisitions, underscoring aggressive pipeline investment. This follows a series of positive clinical and coverage catalysts over the past three months, including strong Phase 3 data for retatrutide and expanded CVS Caremark coverage. The results reinforce Lilly's leadership in the obesity and metabolic disease market, with manufacturing scale and pipeline depth providing a wide moat.
At the time of this announcement, LLY was trading at $1,191.03 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,249.45. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Leverage Shares.